Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

Compound 1

Compound 2

Compound 3 (optional)

Compound 4 (optional)

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=gt20029,pyrilutamide,finasteride

Side-by-side comparison of GT20029, Pyrilutamide, Finasteride
Identity
	GT20029	Pyrilutamide	Finasteride
Class	Investigational topical androgen-receptor degrader (PROTAC), developed by Kintor Pharmaceutical	Investigational topical nonsteroidal androgen-receptor antagonist	Small-molecule 5-alpha-reductase type II inhibitor, supplied as oral tablets
Also listed as	GT-20029, Kintor AR degrader	KX-826, KX826, Pyrilutamide topical	Propecia, Proscar, MK-906
Molecular formula	Not recorded	Not recorded	C23H36N2O2
Molecular weight	Not recorded	Not recorded	372.55 g/mol
CAS	Not recorded	Not recorded	98319-26-7
PubChem CID	Not recorded	Not recorded	57363
Sequence length	Not recorded	Not recorded	Not recorded
Data caveat	None recorded	None recorded	None recorded
United States regulatory status
Status	Investigational	Investigational	FDA-approved drug substance
FDA application	None recorded	None recorded	NDA 020788 (PROPECIA) — approved 19 December 1997
Compounding	No FDA compounding entry recorded	No FDA compounding entry recorded	No FDA compounding entry recorded
WADA	Not named in this record	Not named in this record	Not named in this record
Research profile
Research purpose	Topical androgen-receptor degradation	Topical androgen-receptor blockade	Approved oral androgen-pathway treatment
Proposed mechanism	A topical PROTAC-type molecule intended to mark androgen receptors for degradation, reducing androgen signalling in the follicle. The published Phase 2 trial tests the clinical consequence of that mechanism.	A nonsteroidal androgen-receptor antagonist applied to the scalp, intended to reduce androgen signalling in follicle cells. The clinical advantage over existing treatments is not established.	Inhibits type II 5-alpha-reductase, reducing conversion of testosterone to dihydrotestosterone. Lower scalp DHT slows follicular miniaturisation in responders.
Human evidence	A randomised, placebo-controlled Phase 2 trial in 180 Chinese men with androgenetic alopecia was published in 2025. No Phase 3 trial or approval exists.	Phase 2 trials in men and women and a Phase 3 trial in Chinese men are registered; the Phase 2 studies are listed as completed. No approved product.	Randomised trials in men with mild-to-moderate androgenetic alopecia support the approved indication. It is not approved for women.
Evidence tier	Phase 2 trials registered or reported	Phase 3 trials registered or reported	Approved drug product in the United States
Known safety concerns	Phase 2 adverse events were mostly mild and similar across groups, according to the published report. Long-term effects of sustained androgen-receptor degradation in skin are unknown. No public chemical identity standard was identified, which limits independent quality assessment.	Topical androgen-receptor blockade may still produce systemic effects; the trials are designed to measure this. Phase 3 safety data are not available here as a peer-reviewed report. Long-term safety is unknown.	The label carries warnings and precautions, including sexual adverse experiences and effects on prostate-specific antigen. Finasteride is not indicated for women; the label addresses pregnancy risk. This record is not a complete safety profile or a prescribing guide.
Evidence gaps	Phase 3 confirmation in a broader population. Durability after treatment stops. Long-term safety of local androgen-receptor degradation. A public identity standard for the drug substance.	Peer-reviewed Phase 3 efficacy and safety results. Whether topical delivery avoids meaningful systemic androgen blockade. Durability and any regulatory decision.	Reliable prediction of who will respond. The natural history of reported persistent sexual adverse effects after stopping. Long-term outcomes beyond the trial periods.
Head-to-head evidence	No published head-to-head trial against finasteride, minoxidil or any other hair-loss treatment.	No published head-to-head trial against finasteride or minoxidil.	Dutasteride and finasteride have been compared in trials and reviews, but dutasteride is not FDA-approved for hair loss in the United States.
Named pathways	Androgen receptor · Ubiquitin-proteasome degradation · DHT signalling	Androgen receptor · DHT signalling · Follicular miniaturisation	5-alpha-reductase type II · DHT synthesis · Androgen receptor signalling
Evidence on file
Records	1Open evidence file	2Open evidence file	1Open evidence file
Human-interventional records	1	2	0
Human-observational records	0	0	0
Animal records	0	0	0
In-vitro records	0	0	0
Reviews	0	0	0
Regulatory documents	0	0	1
Earliest indexed	2025	2022	2022
Latest indexed	2025	2024	2022

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.

Overlapping pathways

Named in the mechanism discussion for at least two of these compounds: Androgen receptor · DHT signalling.

Shared biology is not shared evidence. No claim of synergy is made here, and overlapping pathways do not mean the compounds have been studied together.